Phase II trial of stereotactic body radiotherapy with a hydrogel spacer for prostate cancer - Prostate stereotactic body radiotherapy with a hydrogel spacer

The University of Tokyo Hospital0 个研究点目标入组 42 人开始时间: 2017年2月20日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients with lymph node metastasis and or distant metastasis History of prostate cancer treatment (surgery, high intensity focused ultrasound, chemotherapy) Hormone therapy >= 12 months before radiotherapy History of pelvic radiotherapy History of any other malignancy within 2 years (except carcinoma in situ) Severe cardiovascular disease Severe respiratory disease Liver disease (AST, ALT >20 x ULN) Severe kidney disease requiring hemodialysis Unable to provide written informed consent Inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis) History of lowerpelvic surgery Metal in pelvic or near pelvic area (e.g. total hip replacement) affecting pelvic CT scan Bleeding tendency that may disrupt hydrogel spacer insertion (Plt <= 100000, PT INR > 1.5 ULN (with anticoagulant, PT INR > 2.5 ULN), APTT >= 2 x ULN) Unable to insert ultrasound probe (e.g. anal stenosis) Allergic to local anesthetics Considered not appropriate for the study by investigator

发起方